Introduction. New platforms have recently been developed to reduce response time of identification and antimicrobial susceptibility of bacterial isolates in positive blood cultures from patients with bloodstream infections. The Accelerate Pheno TM system (Accelerate Diagnostics, Inc.) provides information on pathogen identification and antibiotic susceptibility in approximately 1.5 and 7 hours, respectively. Methods. In this study we compared the Accelerate Pheno TM system with the standard procedure used in our laboratory. A total of 41 blood cultures were prospectively analysed with the Accelerate Pheno TM system and our standard methods, which include identification by MALDI-TOF mass spectrometry and antibiotic susceptibility testing (AST) by BD Phoenix system and E-test. Results. The correlation between the two methods using Cohen's kappa coefficient was 0.82; mean (sd) time of identification for MALDI-TOF MS was 0.7 (0.22) hours and 1.43 (0.14) hours for the Accelerate PhenoTM system. The mean (sd) time of AST with the BD Phoenix system was 15.85 (2.57) hours and with the Accelerate Pheno TM system 6.7 (0.12) hours. AST results showed an overall essential agreement of 92% for the minimal inhibitory concentrations (MIC) and an overall category agreement of 96%. Among Gram positive isolates, essential and category agreements of 100% were observed. In Gram negative isolates 10 discrepancies were detected, which were classified as 7 major and 3 minor errors. Discrepancies in the Accelerate Pheno TM system were observed particularly for P. aeruginosa. Conclusion. The Accelerate Pheno TM system can improve turnaround time in the management of patients with bloodstream infections.
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Introduction. The management of patients with positive blood culture requires prompt identification and antimicrobial susceptibility testing (AST) since the time to response is critical to implement an adequate antibiotic treatment and to reduce mortality. New platforms are being developed to provide targeted therapy and thus decrease morbidity and mortality rates in sepsis (1) (2) (3) (4) . The Accelerate Pheno TM system (Accelerate Diagnostics, Inc.) is an automated platform that uses single-cell microbiology analysis technology to rapidly identify pathogens (1.5 hours) and to determine antibiotic susceptibility (7 hours) directly from the positive blood culture bottle (5-7). The system combines gel electrofiltration and fluorescence in situ hybridization for bacterial identification, as well as automated microscopy to analyse bacterial growth rates and for extrapolating MIC values (5, 6) . This study prospectively compares the Accelerate Pheno TM system with the matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS, Bruker) for identification and the BD Phoenix system (Becton Dickinson, New Jersey, U.S) for AST.
Methods. The study was designed as a method validation. All laboratory samples were anonymized and unlinked from the hospital database. Only laboratory parameters were recorded and used for this study. No personal or clinical information from patients was used in the study. A total of 41 positive blood cultures were analysed. According to the initial Gram staining, this series contained 18 Gram-negative rods, 21 Gram-positive cocci (9 Staphylococcus spp and 12 Streptococcus spp) and 2 yeasts. The standard procedure used in our laboratory includes direct identification based on the MALDI-TOF MS (Bruker), and antimicrobial susceptibility testing (AST) performed with the BD Phoenix system (Becton Dickinson, New Jersey, U.S) for Gram-negative rods, Staphyloccus aureus and Enterococcus spp. This panel includes information of 34 antibiotics in Gram-positive (Staphyloccus aureus) and 31 en Gramnegative. The Accelerate Pheno TM system panel provides information of 8 antibiotic for Gram-positive and 15 antibiotics for Gram-negative. When S. aureus infection was suspected or the MALDI-TOF MS identified S. aureus, an automated PCR system GenomEra (GenomEra, Alere) was also performed for confirmation (S. aureus and coagulase negative staphylococci) and to detect methicillin resistance (detection of the mecA gene). The identification (ID) and AST of the Accelerate Pheno TM system were performed side by side with our standard microbiological procedure. AST discrepancies between the two methods were resolved using the E-test method.
Results. Table 1 shows the organisms identified using both systems. Although the correlation between the two methods was not perfect, there was a good agreement in terms of microorganism identification (Cohen's kappa coefficient =0.82). The Accelerate Pheno TM system produced three false identifications. In the first case, Accelerate Pheno™ falsely identified S. pneumoniae plus Streptococcus spp in a sample where MALDI-TOF MS showed no identification and the subculture yielded Coagulase negative staphylococci (CNE) and viridians streptococci. In a second case, S. agalactiae plus Streptococcus spp were detected, where the MALDI-TOF and subculture only identified S. agalactiae. Finally, E. faecalis plus P.aeruginosa were identified by Accelerate Pheno TM system, where MALDI-TOF MS and subculture only detected E. faecalis. In two cases the results of the Accelerate Pheno TM system did not correlate with results from the MALDI-TOF MS. In one instance the Accelerate Pheno TM system identified three microorganisms (P.aeruginosa, C.glabrata and S.aureus) whereas MALDI-TOF MS detected only P.aeruginosa which was further confirmed by culture. In a second instance, MALDI identified P. aeruginosa but no identification was provided by Accelerate Pheno™. Direct MALDI-TOF MS was not performed in two yeast positive blood cultures due to low inoculum. In both cases the Accelerate PhenoTM system could not identify these microorganisms (by culture: C. albicans and C. tropicalis). The mean (SD) times of ID for MALDI-TOF MS and for the Accelerate Pheno TM system were 0.7 (0.22) hours and 1.43 (0.14) hours, respectively. The mean (SD) times to AST result with the BD Phoenix system (Becton Dickinson) and with the Accelerate Pheno TM system were 15.85 (2.57) hours and 6.7 (0.12) hours, respectively (Figure 1 ). The AST results showed an overall essential agreement of 92% for the MICs and an overall category agreement of 96%. Among Gram positive isolates essential and category agreements of 100% were observed. However, for S. agalactiae and S. pneumoniae the Accelerate Pheno TM system only produced identification results but no AST. In Gram negative isolates ten discrepancies were detected, 7 major errors and 3 minor errors. In all 10 cases the reference E-test results agreed with the BD Phoenix system. The discrepancy results for AST were observed particularly in P. aeruginosa isolates, where the MICs estimated by the Accelerate Pheno TM system were higher than those reported by the BD Phoenix system. More specifically, the MICs results of piperacillintazobactam were 32 µg/ml with the Accelerate Pheno TM system and <=4 µg/ml with the BD Phoenix system for two isolates. The Accelerate PhenoTM system showed a MIC of 16 µg /ml for Ceftazidime in two strain, but with the BD Phoenix system the MIC was 2 µg/ml in both cases; the Accelerate Pheno TM system showed a MIC of 8 µg/ml and 16 µg/ml for imipenem in two strains, whereas the BD Phoenix system showed a MIC of 2 µg/mL in both cases. Finally, the Accelerate Pheno TM system presented a MIC of 8 µg/mL for gentamicin but with the BD Phoenix system the MIC result was 2 µg/mL. All discrepancies were resolved using E-Test strips which were always in agreement with the BD Phoenix system.
Discussion.
The results of this study support the idea that the Accelerate Pheno TM system may improve turn-around time for identification and AST testing for bacterial bloodstream infections. As previously reported (5-7), in some cases the Accelerate Pheno TM system detected more than one microorganism in mono-microbial infections. In addition, the ID panel failed to show any results for yeasts, which were detected in two cases by subculture. However, we used a previous version of the software; the new version of this software includes an algorithm modification to optimize its performance. A recent study established an overall sensitivity and specificity for yeasts of 83.3% and 98.4%, respectively (8) . The overall essential agreement and the overall category agreement in our study concurs with the multicentre study of Pancholi and colleagues which reported values of 97% (9) . The AST for piperacillin-tazobactam and P. aeruginosa has also been optimized in the latest version of the software (5). The delay in the correct antibiotic therapy in patients with sepsis is a risk factor for mortality (10, 11) . Moreover, a recent study reported shorter times from empirical to final antibiotic treatment using the Accelerate Pheno TM system when compared to conventional phenotypic methods (12) . In our study none of the isolates analysed showed a specific mecha-nism of antibiotic resistance that required changing empirical treatment, but the Accelerate Pheno TM system is capable of detecting different resistance profiles (13, 14) .
In conclusion, the Accelerate Pheno TM system could improve turn-around time in the management of patients with sepsis. The reduced number of samples was a limitation in this study. Further prospective validation studies will determine its costefficacy and clinical effectiveness.
